GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Neuroblastoma (NB) with various clinical presentation is a known childhood malignancy. Despite significant progress in treatment of NB afflicted patients, high risk disease is usually associated with poor outcome, resulting in long‐term survival of less that 50%. Known as a disease most commonly originated form the nerve roots, the variants involved in NB imitation and progression remain to be elucidated. The outcome of low to intermediate risk disease is favorable whereas the high risk NB disease with dismal prognosis, positing the necessity of novel approaches for early detection and prognostication of advanced disease. Tailored immunotherapy approaches have shown significant improvement in high‐risk NB patients. It has found a link between Gangliosides and progression of NB. The vast majority of neuroblastoma tumors express elevated levels of GD2, opening new insight into using anti‐GD2 drugs as potential treatments for NBs. Implication of anti‐GD2 monoclonal antibodies for treatment of high risk NBs triggers further investigation to unearth novel biomarkers as prognostic and response biomarker to guide additional multimodal tailored treatment approaches. A growing body of evidence supports the usefulness of miRNAs to evaluate high risk NBs response to anti‐GD2 drugs and further prevent drug‐related toxicities in refractory or recurrent NBs. miRNAs and circulating proteins in body fluids (plasma and serum) present as potential biomarkers in early detection of NBs. Here, we summarize various biomarkers involved in diagnosis, prognosis and response to treatment in patients with NB. We further attempted to overview prognostic biomarkers in response to treatment with anti‐GD2 drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835 · cited 2×
“Hence, peripheral nerves and melanocytes can be suitable target for systemic tumor immunotherapy (Yu et al., 2010; Yang & Sondel, 2010).”
BackgroundThe miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-β Pathway in Neuroblastoma
Mestdagh, P., Boström, A.-K., Impens, F., Fredlund, E., Van Peer, G., De Antonellis, P., von Stedingk, K., Ghesquière, B., Schulte, S., Dews, M., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.11.038 · Cited by 314
Glioblastoma: exosome and microRNA as novel diagnosis biomarkers
Saadatpour, L., Fadaee, E., Fadaei, S., Nassiri Mansour, R., Mohammadi, M., Mousavi, S. M., Goodarzi, M., Verdi, J., & Mirzaei, H. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.48 · Cited by 244
Self-citationIdentification of epigenetically regulated genes that predict patient outcome in neuroblastoma
Carén, H., Djos, A., Nethander, M., Sjöberg, R.-M., Kogner, P., Enström, C., Nilsson, S., & Martinsson, T. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-66 · Cited by 74 · cited 1×
“(2008) KRT19 RT-PCR/ cDNA Microarray 11/43 Nozato, Kaneko, Nakagawara, and Komuro (2013); Caren et al. (2011)”
Cited by
The role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735
NLRP3 inflammasome: Its regulation and involvement in atherosclerosis
Hoseini, Z., Sepahvand, F., Rashidi, B., Sahebkar, A., Masoudifar, A., & Mirzaei, H. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25930 · Cited by 458
Self-citationBreast cancer diagnosis: Imaging techniques and biochemical markers
Jafari, S. H., Saadatpour, Z., Salmaninejad, A., Momeni, F., Mokhtari, M., Nahand, J. S., Rahmati, M., Mirzaei, H., & Kianmehr, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26379 · Cited by 410
Self-citationMicroRNA: A novel target of curcumin in cancer therapy
Mirzaei, H., Masoudifar, A., Sahebkar, A., Zare, N., Sadri Nahand, J., Rashidi, B., Mehrabian, E., Mohammadi, M., Mirzaei, H. R., & Jaafari, M. R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26055 · Cited by 236
Self-citationExosomes and microRNAs: New potential therapeutic candidates in Alzheimer disease therapy
Iranifar, E., Seresht, B. M., Momeni, F., Fadaei, E., Mehr, M. H., Ebrahimi, Z., Rahmati, M., Kharazinejad, E., & Mirzaei, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27214 · Cited by 93
Self-citation
Metadata
- Authors
- Gholamin, S., Mirzaei, H., Razavi, S., Hassanian, S. M., Saadatpour, L., Masoudifar, A., ShahidSales, S., & Avan, A.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2017-05-23
- Volume
- 233
- Issue
- 2
- Pages
- 866-879
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2592579739
- Cited by
- 105
- References
- 4
- FWCI
- 13.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.